Core Viewpoint - Deep Longevity, Inc. plans to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2]. Group 1: Expansion Plans - Deep Longevity will establish a local sales team in the U.S., with the first two sales personnel joining on January 1, 2026 [2]. - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2]. Group 2: Product Offerings - The company offers clinically validated aging clocks, including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, which provide multi-dimensional biological age assessments beyond chronological age [1][2]. - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, integrating blood biomarkers, epigenetics, psychology, and biology to deliver comprehensive biological aging profiles [2]. Group 3: Business Model - Deep Longevity provides vertical software-as-a-service (SaaS) solutions that offer personalized recommendations to improve health and extend healthy lifespan [3].

Group 1: Company Updates - Licheng Pacific (00575) announced that its strategic partner, Jiangsu Wanbang Biopharmaceutical Group, is advancing the new drug application for Senstend with the National Medical Products Administration of China [1] - Jiangsu Wanbang has received the first round of inquiries regarding the new drug application and has submitted a comprehensive response [1] - To support the new drug application, Jiangsu Wanbang submitted 900 commercial samples of Senstend produced by its manufacturing partners [1] - Jiangsu Wanbang remains optimistic about obtaining approval for the new drug application by the end of 2025 and plans to commercialize it in the first quarter of 2026 [1] Group 2: Deep Longevity Developments - Deep Longevity, Inc. has made significant progress in acquiring new clients, including Humansa Health in Hong Kong and Holistica World in India [2] - There has been an increase in the usage of Deep Longevity's aging clock among clients compared to the same period last year, indicating the growing value of the technology [2] - The company aims to establish new partnerships with B2C longevity applications, platforms, startups, and diagnostic companies [2] - Deep Longevity is focused on launching its aging clock in the U.S. market and has appointed a U.S. president to lead market expansion efforts [2] - The longevity and wellness market is estimated to be worth over $6.3 trillion in 2023, highlighting its potential for growth [2] Group 3: Product Innovations - Deep Longevity is actively engaging with longevity clinics and companies in Brazil, Germany, and Southeast Asia regarding the use of its aging clock [3] - The company has updated its biometric age feature, which now includes 17 blood biomarkers and 4 biological measurements, providing clients with additional metrics [3] - Deep Longevity is continuously updating its large language model to offer more accurate BloodAge and MindAge reports [3] - The company is researching the addition of a new clock focused on facial age or facial index score to its product line, along with other health, beauty, and wellness-focused clocks [3]